Scientists at Oxford University are racing against time to develop a new vaccine aimed at combating the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC). This urgent initiative comes in light of the outbreak, which has resulted in approximately 750 suspected cases and 177 fatalities. The strain of the virus responsible for this outbreak, known as Bundibugyo, is particularly concerning as it has no proven vaccine and poses a mortality rate of around 33% for those infected.
Current Situation in the DRC
The World Health Organization (WHO) has recently escalated the risk level associated with this outbreak from “high” to “very high” within the DRC, while also categorising the broader regional threat as high. However, the international risk remains low. This assessment follows the WHO’s declaration of a public health emergency of international concern last Sunday, clarifying that the outbreak does not constitute a pandemic.
The urgency surrounding the development of a vaccine is palpable. As scientists in Oxford work diligently, they are aware that the situation could worsen, necessitating swift intervention with their experimental vaccine.
Innovative Vaccine Technology
The new vaccine leverages the ChAdOx1 technology, which was previously employed during the COVID-19 pandemic. This adaptable platform can be modified to target various infections quickly. For this Ebola vaccine, the genetic code from the Bundibugyo strain has been incorporated into a modified cold virus that typically infects chimpanzees. This engineered virus is designed to safely deliver crucial genetic material to human cells, training the immune system to recognise and combat the Ebola virus without causing infection or symptoms.
Animal trials for the vaccine have already commenced in Oxford, with plans for rapid mass production by the Serum Institute of India once the necessary medical-grade materials are available. Professor Teresa Lambe, the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group, emphasised the importance of quick action, stating, “Once we get starting material to them they can go fast and they can go big.”
Vaccination Strategy
The deployment of the vaccine will differ from the mass immunisation strategies seen during the COVID-19 pandemic. Instead, a targeted approach known as ring vaccination will be implemented. This method involves immunising only those at the highest risk of infection, such as close contacts of confirmed cases and healthcare workers treating patients who may be highly infectious.
Despite the existence of a vaccine for the more prevalent Zaire species of Ebola, Bundibugyo remains a challenge due to the lack of a proven vaccine. While another experimental vaccine for Bundibugyo is in the pipeline, it is expected to take an additional six to nine months before it can be tested.
The Scientific Community’s Commitment
The scientific community is acutely aware of the historical context of this outbreak. Bundibugyo has been responsible for only two previous outbreaks, in Uganda in 2007 and in the DRC in 2012, and has not been observed for over a decade. The urgency of the current situation has led researchers at Oxford to draw on their previous work with similar vaccines targeting the Sudan species of Ebola and the Marburg virus.
As the situation unfolds, experts remain hopeful that the combination of swift scientific innovation and public health measures, such as contact tracing and quarantine, will mitigate the impact of the outbreak.
Why it Matters
The development of a new Ebola vaccine is crucial not just for the immediate health of the DRC but also for global public health preparedness. The speed and efficiency of this research underscore a growing commitment to addressing infectious diseases that can threaten communities worldwide. As scientists work tirelessly to bring this vaccine to fruition, the world watches, understanding that effective response strategies are vital to prevent the spread of such deadly viruses.
